Feasibility and efficacy of early docetaxel plus androgen deprivation therapy for metastatic hormone-sensitive prostate cancer in a rural health care setting.
Carsten NiederLuka StanisavljevicAstrid DalhaugEllinor Christin HauklandPublished in: Scandinavian journal of urology (2022)
In this rural health care setting, early docetaxel was feasible and effective in reducing progression to mCRPC and prolonging survival. Median survival was very close to the 58 months reported in the CHAARTED trial.